CRISPR Therapeutics AG (NASDAQ: CRSP) saw its stock plummet 8.46% in Tuesday's trading session after the company reported disappointing second-quarter financial results. The gene-editing focused biopharmaceutical firm's revenue fell significantly short of analyst expectations, while its net loss widened year-over-year.

For the quarter ended June 30, 2025, CRISPR Therapeutics reported revenue of $892,000, missing the analyst consensus estimate of $6.255 million by a wide margin. This represents a 72.53% increase from the same period last year but failed to meet market expectations. The company's net loss expanded to $208.5 million, or $2.40 per share, compared to a loss of $126.4 million, or $1.49 per share, in the second quarter of 2024. The increased loss was partly due to a $96.3 million expense for acquired in-process research and development.

Despite the financial setback, CRISPR Therapeutics highlighted progress in its pipeline, including the activation of 75 authorized treatment centers for its CASGEVY therapy and advancements in various clinical trials. The company maintains a strong balance sheet with approximately $1.7 billion in cash and marketable securities. However, investors seemed to focus on the near-term financial performance, leading to the significant stock decline.